Mazdutide 9mg Enters NMPA Review, Advancing Obesity Treatment
BEIJING, China, Nov. 25, 2025 — Innovent Biologics and Eli Lilly announced that the supplementary application for Mazdutide 9mg...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
BEIJING, China, Nov. 25, 2025 — Innovent Biologics and Eli Lilly announced that the supplementary application for Mazdutide 9mg...
